A Phase 2 interventional study of RTS,S/AS01E and RTS,S/AS01B in Malaria, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-27.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Malaria by GlaxoSmithKline — 3 open to participants now, 3 under way, none of them phase 3. Malaria · GlaxoSmithKline.
Among the 41 studies in Malaria by GlaxoSmithKline, this one is the 24th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2017, is one of 18 in phase 2, and was the 34th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →3 of the 41 studies in Malaria by GlaxoSmithKline are open now, in 4 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Gabon, Uganda
Ages 18–65
GlaxoSmithKline · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
GlaxoSmithKline · Sites in Rwanda
Ages 5 mo–60 mo · Healthy volunteers
By country, each count listing its studies:
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is below the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 207 across the 38 interventional studies, 36,366 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Malaria by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07036159GlaxoSmithKlineA Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months | 2027-04-23 |
| NCT07545681GlaxoSmithKlineA Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria | 2027-10-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Malaria by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate efficacy, immunogenicity and safety of various dose schedules of GSK Biologicals' candidate malaria vaccines RTS,S/AS01B (adult formulation) and RTS,S/AS01E (pediatric formulation) in healthy malaria-naïve subjects aged 18-55 years. The purpose of this study is to investigate whether changes in dosing schedule are associated with increased or equivalent protection, and to evaluate the immune mechanisms associated with vaccine efficacy under varying dosing schedules.
Protocol Amendment 1 incorporated: additional blood sampling for assessment of parasitemia (polymerase chain reaction [PCR] testing); clarification that blood samples for both peripheral blood mononuclear cells (PBMC) and plasma will be collected for repository storage; revision of volume of whole blood samples to be taken for parasitemia assessment; clarification that urine pregnancy tests will be conducted for all females and not just those of childbearing potential; deletion of visit at Day 1 post day of challenge; clarification that RNA sequencing and not deep sequencing will be performed in this study.
Note that as a result of internal change in data standards terminology, the study data collected was converted to cDISC and the statistical analysis plan was amended accordingly. "Day 0" in the study design was replaced by "Day 1"; consequently, "Day n" was replaced by "Day n+1". Thus, the timeframes (Day 0, Day n) of Outcome Measures described in this study record are different to that denoted in the full protocol document posted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment. Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.
Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
Biological: RTS,S/AS01E · Procedure: Sporozoite-infected mosquitoes challenge.
Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
Biological: RTS,S/AS01E · Procedure: Sporozoite-infected mosquitoes challenge.
Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.
Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
Biological: RTS,S/AS01B · Procedure: Sporozoite-infected mosquitoes challenge.
Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
Procedure: Sporozoite-infected mosquitoes challenge.
Subjects will receive intramuscular injection of RTS,S/AS01E.
Subjects will receive intramuscular injection of RTS,S/AS01B.
Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed. The challenge occurs approximately 90 days (three months) after the last vaccination. Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.
Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls
Occurrence of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge. Post-challenge, parasitemia was determined by microscopy of Giemsa-stained thick blood films (smear). Microscopy was performed on thick smears using a validated standard operation procedure. For the analysis of proportion affected (relative risk), all subjects included in the analysis were considered at risk of infection and no censoring or elimination was applied for subjects not completing the entire protocol defined post challenge follow-up (Day 315 - 28 days post challenge).
Time frame: Following sporozoite challenge starting 3 months after the last vaccine dose (Day 287) for up to 28 days post-challenge (Day 315).
Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule
For the analyses of time to onset of parasitemia, time at risk started on first day of challenge. Time at risk was censored on Day 315 (28 days post challenge), drop-out date, start date of antimalarial treatment or date meeting an endpoint, whichever occurs first.
Time frame: Following sporozoite challenge starting 3 months after the last vaccine dose (at Day 287) for up to 28 days post-challenge (at Day 315).
Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations
Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU/mL). The cut-off for the assay was 1.9 EU/mL. The GMC calculations were performed by taking the anti-log of the mean of the log transformations (base 10). Antibody concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off (=1.0) for the purpose of GMC calculation.
Time frame: At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group
Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations
Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU/ml). The cut-off for the assay was 6.2 mIU/mL.
Time frame: At Day 1, Day 59, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from AduFx, 2PedFx, PedFx, and Adu2Fx Groups. At Day 1, Day 197, Day 227, Day 287, Day 315, and Day 377 for subjects from Adu1Fx Group
Number of Subjects With Any Solicited Local Symptoms
Solicited local symptoms assessed are pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm).
Time frame: Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.
Number of Subjects With Any Solicited General Symptoms
Solicited general symptoms assessed are fatigue, gastrointestinal symptoms, headache and fever. Any occurrence of symptom regardless of intensity grade. Fever was defined as temperature equal or greater than (≥) 37.5 degrees Celsius (°C) for oral route, axillary or tympanic route or 38.0°C for rectal route.
Time frame: Within the 7-day period (Days 1-7) after dose 1, dose 2 (except for Adu1Fx Group) and dose 3.
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination
An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within the 30-day period (Days 1-30), after any vaccination (across doses)
Number of Subjects With Any Unsolicited AEs After Challenge
An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Within the 30-day (Days 1-30) period post-challenge
Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Within the 30-day period (Days 1-30) after any vaccination (across doses)
Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Day 1 up to study conclusion (Day 377)
Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination
An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Day 1 up to study conclusion (Day 377)
Number of Subjects With Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From Day 1 up to study conclusion (Day 377)
Number of Subjects With Meningitis
Meningitis is to be reported as an adverse event of specific interest and tabulated per study group.
Time frame: From Day 1 up to study conclusion (Day 377)
Number of Subjects With Abnormal Laboratory Values Gradings
Biochemistry (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\] and creatinine) and hematological (hemoglobin, platelets, White Blood Cells \[WBC\] decrease and WBC increase) laboratory values were presented according to toxicity grading scales (Grade 0 \[GR0\], Grade 1 \[GR1\], Grade 2 \[GR2\] Grade 3 \[GR3\]) and tabulated by group. Grading scale is taken from the \[FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)\].
Time frame: At Visit 1 Screening (Day -89 to Day 1), Day 36, Day 59, Day 204, Day 227, between Day 292 & Day 313, and Day 315 for each vaccinated subject.For Infectivity Control subjects at Visit 1b Screening (Day 231 to Day 287),between Day 292 & Day 313,and Day 315
Number of Subjects With Any, Fatal or Related SAE, After Challenge
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From day of challenge (Day 287) to the end of the challenge phase (Day 315)
| Milestone | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Started | 26 | 26 | 26 | 26 | 26 | 24 |
| Completed | 20 | 21 | 22 | 19 | 21 | 24 |
| Not completed | 6 | 5 | 4 | 7 | 5 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 | 1 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Missed vaccination, exclusion criteria | 2 | 2 | 2 | 4 | 3 | 0 |
Occurrence of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge. Post-challenge, parasitemia was determined by microscopy of Giemsa-stained thick blood films (smear). Microscopy was performed on thick smears using a validated standard operation procedure. For the analysis of proportion affected (relative risk), all subjects included in the analysis were considered at risk of infection and no censoring or elimination was applied for subjects not completing the entire protocol defined post challenge follow-up (Day 315 - 28 days post challenge).
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls | 9 | 5 | 8 | 9 | 15 | 22 |
For the analyses of time to onset of parasitemia, time at risk started on first day of challenge. Time at risk was censored on Day 315 (28 days post challenge), drop-out date, start date of antimalarial treatment or date meeting an endpoint, whichever occurs first.
| Days | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule | 14.8 ± 1.2 | 14.6 ± 1.1 | 14.3 ± 2.0 | 14.9 ± 2.1 | 14.2 ± 2.4 | 12.7 ± 1.9 |
Anti-CS antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in Enzyme-linked immunosorbent assay Unit per milliliter (EU/mL). The cut-off for the assay was 1.9 EU/mL. The GMC calculations were performed by taking the anti-log of the mean of the log transformations (base 10). Antibody concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off (=1.0) for the purpose of GMC calculation.
| EU/mL | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| At Day 1 | 1 (1.0 to 1.0) | 1 (1.0 to 1.0) | 1 (1.0 to 1.0) | 1 (1.0 to 1.0) | 1 (1.0 to 1.0) |
| At Day 59 | 108.2 (70.1 to 167.0) | 107.8 (73.0 to 159.1) | 53.8 (39.0 to 74.1) | 61.7 (47.6 to 79.9) | — |
| At Day 197 | 30 (17.9 to 50.5) | 39.3 (23.8 to 64.8) | 15.1 (9.3 to 24.5) | 19.4 (13.2 to 28.5) | 3.8 (2.0 to 7.2) |
| At Day 227 | 85.9 (50.8 to 145.5) | 79.8 (54.7 to 116.6) | 50.2 (35.5 to 70.9) | 64 (42.8 to 95.8) | 22.1 (12.0 to 40.8) |
| At Day 287 | 61.4 (34.7 to 108.8) | 57.6 (38.2 to 87.1) | 34.4 (23.1 to 51.1) | 38.1 (20.8 to 69.9) | 12.3 (6.2 to 24.4) |
| At Day 315 | 56.6 (32.5 to 98.4) | 51 (33.3 to 78.0) | 31.3 (21.2 to 46.3) | 44.1 (27.8 to 70.1) | 10.6 (5.2 to 21.5) |
| At Day 377 | 43.7 (24.9 to 76.8) | 38.1 (24.3 to 59.8) | 25 (16.5 to 37.9) | 31.7 (19.6 to 51.3) | 9.5 (4.8 to 19.0) |
Anti-HBs IgG antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milli-International Unit per milliliter (mIU/ml). The cut-off for the assay was 6.2 mIU/mL.
| mIU/mL | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| At Day 1 | 44.1 (15.6 to 124.3) | 68.8 (20.4 to 231.7) | 45.7 (15.2 to 137.5) | 21.8 (9.0 to 52.6) | 16 (6.5 to 39.6) |
| At Day 59 | 42616.7 (12325.1 to 147356.7) | 28894.8 (8705.8 to 95903.3) | 26149.3 (8588.7 to 79615.2) | 14710.6 (3837.0 to 56398.8) | — |
| At Day 197 | 19369.3 (8325.5 to 45062.6) | 15358.8 (5971.2 to 39505.1) | 11269.1 (4892.1 to 25958.8) | 6846.7 (2273.5 to 20618.8) | 2031.7 (715.9 to 5766.4) |
| At Day 227 | 45959.9 (27093.8 to 77962.8) | 30994.5 (15352.8 to 62572.4) | 28560.6 (15532.4 to 52516.4) | 26717 (12916.3 to 55263.3) | 35620.9 (22337.4 to 56803.7) |
| At Day 287 | 36266.3 (21828.7 to 60252.9) | 20712.2 (10050.4 to 42684.5) | 19126.1 (9889.0 to 36991.5) | 13911.3 (4939.4 to 39179.9) | 16376.8 (9798.1 to 27372.8) |
| At Day 315 | 33027.7 (19159.7 to 56933.4) | 18527.8 (8862.8 to 38732.5) | 17465.5 (8798.2 to 34671.2) | 16685 (8192.0 to 33982.9) | 12609.9 (7499.3 to 21203.5) |
| At Day 377 | 27823 (15910.1 to 48655.8) | 15083.7 (6953.8 to 32718.4) | 13716 (6456.7 to 29136.9) | 11257.6 (5164.7 to 24538.5) | 10975.2 (5889.9 to 20451.3) |
Solicited local symptoms assessed are pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm).
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| Pain, dose 1 | 23 | 21 | 22 | 22 | 19 |
| Redness, dose 1 | 8 | 11 | 4 | 8 | 9 |
| Swelling, dose 1 | 5 | 12 | 3 | 4 | 5 |
| Pain, dose 2 | 20 | 16 | 20 | 12 | — |
| Redness, dose 2 | 8 | 10 | 5 | 4 | — |
| Swelling, dose 2 | 5 | 8 | 6 | 3 | — |
| Pain, dose 3 | 11 | 12 | 13 | 16 | 15 |
| Redness, dose 3 | 7 | 10 | 10 | 11 | 6 |
| Swelling, dose 3 | 3 | 6 | 5 | 3 | 3 |
Solicited general symptoms assessed are fatigue, gastrointestinal symptoms, headache and fever. Any occurrence of symptom regardless of intensity grade. Fever was defined as temperature equal or greater than (≥) 37.5 degrees Celsius (°C) for oral route, axillary or tympanic route or 38.0°C for rectal route.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| Fatigue, dose 1 | 13 | 14 | 13 | 10 | 11 |
| Gastrointestinal symptoms, dose 1 | 5 | 8 | 5 | 4 | 6 |
| Headache, dose 1 | 15 | 14 | 10 | 12 | 9 |
| Fever, dose 1 | 3 | 6 | 2 | 3 | 3 |
| Fatigue, dose 2 | 11 | 12 | 10 | 6 | — |
| Gastrointestinal symptoms, dose 2 | 3 | 6 | 7 | 3 | — |
| Headache, dose 2 | 13 | 14 | 11 | 6 | — |
| Fever, dose 2 | 6 | 6 | 3 | 1 | — |
| Fatigue, dose 3 | 4 | 6 | 8 | 11 | 8 |
| Gastrointestinal symptoms, dose 3 | 4 | 2 | 6 | 0 | 5 |
| Headache, dose 3 | 6 | 7 | 6 | 9 | 9 |
| Fever, dose 3 | 0 | 2 | 0 | 2 | 0 |
An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited adverse event is any event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination | 18 | 18 | 15 | 17 | 10 |
An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Any Unsolicited AEs After Challenge | 0 | 0 | 0 | 0 | 0 | 0 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group |
|---|---|---|---|---|---|
| Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination | 0 | 0 | 0 | 0 | 0 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination | 0 | 0 | 0 | 0 | 0 | 0 |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Potential Immune Mediated Diseases (pIMDs) | 0 | 0 | 0 | 0 | 0 | 0 |
Meningitis is to be reported as an adverse event of specific interest and tabulated per study group.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Meningitis | 0 | 0 | 0 | 0 | 0 | 0 |
Biochemistry (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\] and creatinine) and hematological (hemoglobin, platelets, White Blood Cells \[WBC\] decrease and WBC increase) laboratory values were presented according to toxicity grading scales (Grade 0 \[GR0\], Grade 1 \[GR1\], Grade 2 \[GR2\] Grade 3 \[GR3\]) and tabulated by group. Grading scale is taken from the \[FDA guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (September 2007)\].
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Alanine Aminotransferase, SCR, Gr0 | 25 | 24 | 25 | 25 | 26 | 24 |
| Alanine Aminotransferase, SCR, Gr1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Alanine Aminotransferase, SCR, Gr2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Alanine Aminotransferase, D36, Gr0 | 26 | 24 | 25 | 25 | — | — |
| Alanine Aminotransferase, D36, Gr1 | 0 | 1 | 0 | 1 | — | — |
| Alanine Aminotransferase, D59, Gr0 | 26 | 24 | 24 | 24 | — | — |
| Alanine Aminotransferase, D59, Gr1 | 0 | 1 | 1 | 2 | — | — |
| Alanine Aminotransferase, D204, Gr0 | 21 | 22 | 24 | 24 | 20 | — |
| Alanine Aminotransferase, D204, Gr1 | 2 | 2 | 0 | 1 | 3 | — |
| Alanine Aminotransferase, D227, Gr0 | 22 | 20 | 23 | 23 | 22 | — |
| Alanine Aminotransferase, D227, Gr1 | 1 | 2 | 1 | 1 | 1 | — |
| Alanine Aminotransferase, D227, Gr2 | 0 | 1 | 0 | 0 | 0 | — |
| Alanine Aminotransferase, D292, Gr0 | 9 | 4 | 7 | 8 | 10 | 22 |
| Alanine Aminotransferase, D292, Gr1 | 0 | 0 | 1 | 1 | 5 | 0 |
| Alanine Aminotransferase, D292, Gr2 | 0 | 1 | 0 | 0 | 0 | 1 |
| Alanine Aminotransferase, D315, Gr0 | 16 | 20 | 18 | 18 | 18 | 21 |
| Alanine Aminotransferase, D315, Gr1 | 3 | 1 | 4 | 2 | 2 | 3 |
| Alanine Aminotransferase, D315, Gr2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Aspartate Aminotransferase, SCR, Gr0 | 26 | 25 | 25 | 25 | 26 | 23 |
| Aspartate Aminotransferase, SCR, Gr1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Aspartate Aminotransferase, D36, Gr0 | 26 | 25 | 24 | 26 | — | — |
| Aspartate Aminotransferase, D36, Gr1 | 0 | 0 | 1 | 0 | — | — |
| Aspartate Aminotransferase, D59, Gr0 | 26 | 24 | 24 | 25 | — | — |
| Aspartate Aminotransferase, D59, Gr1 | 0 | 1 | 1 | 1 | — | — |
| Aspartate Aminotransferase, D204, Gr0 | 22 | 23 | 24 | 25 | 22 | — |
| Aspartate Aminotransferase, D204, Gr1 | 1 | 1 | 0 | 0 | 1 | — |
| Aspartate Aminotransferase, D227, Gr0 | 23 | 22 | 23 | 23 | 22 | — |
| Aspartate Aminotransferase, D227, Gr1 | 0 | 0 | 1 | 0 | 1 | — |
| Aspartate Aminotransferase, D227, Gr2 | 0 | 1 | 0 | 1 | 0 | — |
| Aspartate Aminotransferase, D292, Gr0 | 9 | 4 | 7 | 9 | 13 | 22 |
| Aspartate Aminotransferase, D292, Gr1 | 0 | 0 | 1 | 0 | 2 | 0 |
| Aspartate Aminotransferase, D292, Gr2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Aspartate Aminotransferase, D292, Gr3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase, D315, Gr0 | 20 | 21 | 21 | 18 | 20 | 24 |
| Aspartate Aminotransferase, D315, Gr1 | 0 | 0 | 1 | 2 | 1 | 0 |
| Creatinine, SCR, Gr0 | 26 | 26 | 26 | 25 | 26 | 24 |
| Creatinine, SCR, Gr1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatinine, D36, Gr0 | 25 | 25 | 25 | 26 | — | — |
| Creatinine, D36, Gr1 | 1 | 0 | 0 | 0 | — | — |
| Creatinine, D59, Gr0 | 26 | 25 | 25 | 26 | — | — |
| Creatinine, D204, Gr0 | 23 | 24 | 24 | 25 | 22 | — |
| Creatinine, D204, Gr1 | 0 | 0 | 0 | 0 | 1 | — |
| Creatinine, D227, Gr0 | 23 | 23 | 24 | 24 | 22 | — |
| Creatinine, D227, Gr1 | 0 | 0 | 0 | 0 | 1 | — |
| Creatinine, D292, Gr0 | 9 | 5 | 8 | 8 | 15 | 22 |
| Creatinine, D292, Gr1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatinine, D292, UNK | 0 | 0 | 0 | 0 | 0 | 1 |
| Creatinine, D315, Gr0 | 20 | 21 | 21 | 20 | 20 | 24 |
| Creatinine, D315, Gr1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Hemoglobin, SCR, Gr0 | 26 | 26 | 26 | 26 | 26 | 23 |
| Hemoglobin, SCR, Gr1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hemoglobin, D36, Gr0 | 23 | 24 | 22 | 25 | — | — |
| Hemoglobin, D36, Gr1 | 3 | 1 | 3 | 1 | — | — |
| Hemoglobin, D59, Gr0 | 25 | 25 | 24 | 25 | — | — |
| Hemoglobin, D59, Gr1 | 1 | 0 | 1 | 1 | — | — |
| Hemoglobin, D204, Gr0 | 20 | 24 | 21 | 25 | 23 | — |
| Hemoglobin, D204, Gr1 | 3 | 0 | 3 | 0 | 0 | — |
| Hemoglobin, D227, Gr0 | 19 | 23 | 23 | 23 | 23 | — |
| Hemoglobin, D227, Gr1 | 4 | 0 | 1 | 1 | 0 | — |
| Hemoglobin, D292, Gr0 | 9 | 5 | 8 | 8 | 15 | 23 |
| Hemoglobin, D292, Gr1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemoglobin, D315, Gr0 | 16 | 21 | 19 | 18 | 21 | 24 |
| Hemoglobin, D315, Gr1 | 4 | 0 | 3 | 1 | 0 | 0 |
| Hemoglobin, D315, Gr2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelets, SCR, Gr0 | 26 | 26 | 26 | 26 | 26 | 24 |
| Platelets, D36, Gr0 | 26 | 25 | 25 | 26 | — | — |
| Platelets, D59, Gr0 | 26 | 25 | 25 | 26 | — | — |
| Platelets, D204, Gr0 | 23 | 24 | 24 | 25 | 23 | — |
| Platelets, D227, Gr0 | 23 | 23 | 24 | 24 | 23 | — |
| Platelets, D292, Gr0 | 9 | 5 | 8 | 8 | 15 | 19 |
| Platelets, D292, Gr1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Platelets, D292, Gr2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelets, D292, Gr3 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelets, D315, Gr0 | 20 | 21 | 22 | 19 | 21 | 22 |
| Platelets, D315, Gr1 | 0 | 0 | 0 | 1 | 0 | 1 |
| WBC Decrease, SCR, Gr0 | 25 | 25 | 26 | 26 | 26 | 24 |
| WBC Decrease, SCR, Gr1 | 1 | 1 | 0 | 0 | 0 | 0 |
| WBC Decrease, D36, Gr0 | 26 | 24 | 25 | 26 | — | — |
| WBC Decrease, D36, Gr1 | 0 | 1 | 0 | 0 | — | — |
| WBC Decrease, D59, Gr0 | 26 | 25 | 24 | 26 | — | — |
| WBC Decrease, D59, Gr1 | 0 | 0 | 1 | 0 | — | — |
| WBC Decrease, D204, Gr0 | 23 | 24 | 24 | 25 | 23 | — |
| WBC Decrease, D227, Gr0 | 23 | 23 | 22 | 24 | 23 | — |
| WBC Decrease, D227, Gr1 | 0 | 0 | 2 | 0 | 0 | — |
| WBC Decrease, D292, Gr0 | 8 | 4 | 6 | 8 | 15 | 20 |
| WBC Decrease, D292, Gr1 | 1 | 1 | 2 | 1 | 0 | 3 |
| WBC Decrease, D315, Gr0 | 20 | 21 | 21 | 20 | 20 | 24 |
| WBC Decrease, D315, Gr1 | 0 | 0 | 1 | 0 | 1 | 0 |
| WBC Increase, SCR, Gr0 | 25 | 26 | 26 | 25 | 25 | 22 |
| WBC Increase, SCR, Gr1 | 1 | 0 | 0 | 1 | 1 | 2 |
| WBC Increase, D36, Gr0 | 25 | 25 | 25 | 23 | — | — |
| WBC Increase, D36, Gr1 | 1 | 0 | 0 | 3 | — | — |
| WBC Increase, D59, Gr0 | 26 | 25 | 25 | 26 | — | — |
| WBC Increase, D204, Gr0 | 23 | 24 | 24 | 23 | 21 | — |
| WBC Increase, D204, Gr1 | 0 | 0 | 0 | 2 | 2 | — |
| WBC Increase, D227, Gr0 | 22 | 23 | 23 | 24 | 23 | — |
| WBC Increase, D227, Gr1 | 1 | 0 | 1 | 0 | 0 | — |
| WBC Increase, D292, Gr0 | 9 | 5 | 8 | 9 | 15 | 23 |
| WBC Increase, D315, Gr0 | 19 | 20 | 22 | 20 | 19 | 24 |
| WBC Increase, D315, Gr1 | 0 | 0 | 0 | 0 | 2 | 0 |
| WBC Increase, D315, Gr2 | 0 | 1 | 0 | 0 | 0 | 0 |
| WBC Increase, D315, Gr3 | 1 | 0 | 0 | 0 | 0 | 0 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Any, Fatal or Related SAE, After Challenge | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Solicited adverse events were reported during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period after vaccination. Serious adverse events were reported during the whole study period (from Day 1 up to study conclusion at Day 377).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AduFx Group | 0/26 (0%) | 0/26 (0%) | 26/26 (100%) |
| 2PedFx Group | 0/26 (0%) | 0/26 (0%) | 25/26 (96.2%) |
| PedFx Group | 0/26 (0%) | 0/26 (0%) | 23/26 (88.5%) |
| Adu2Fx Group | 0/26 (0%) | 0/26 (0%) | 25/26 (96.2%) |
| Adu1Fx Group | 0/26 (0%) | 0/26 (0%) | 24/26 (92.3%) |
| Control Group | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Event | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 23/26 | 23/26 | 23/26 | 22/26 | 20/26 | 0/24 |
| FatigueGeneral disorders | 16/26 | 20/26 | 15/26 | 13/26 | 14/26 | 0/24 |
| HeadacheNervous system disorders | 20/26 | 20/26 | 18/26 | 16/26 | 12/26 | 0/24 |
| Injection site erythemaGeneral disorders | 14/26 | 18/26 | 12/26 | 15/26 | 12/26 | 0/24 |
| Injection site swellingGeneral disorders | 9/26 | 15/26 | 9/26 | 9/26 | 8/26 | 0/24 |
| PyrexiaGeneral disorders | 8/26 | 12/26 | 4/26 | 5/26 | 3/26 | 0/24 |
| Gastrointestinal disorderGastrointestinal disorders | 9/26 | 11/26 | 9/26 | 6/26 | 8/26 | 0/24 |
| Upper respiratory tract infectionInfections and infestations | 1/26 | 3/26 | 3/26 | 7/26 | 2/26 | 0/24 |
| ChillsGeneral disorders | 4/26 | 3/26 | 5/26 | 5/26 | 0/26 | 0/24 |
| MalaiseGeneral disorders | 1/26 | 2/26 | 1/26 | 1/26 | 0/26 | 0/24 |
| Age, Continuous(Years) | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group | Total |
|---|---|---|---|---|---|---|---|
| Mean | 31.7 ± 8.4 | 30.8 ± 9.6 | 32.0 ± 10.4 | 32.4 ± 10.9 | 32.2 ± 10.3 | 34.6 ± 11.9 | 32.3 ± 10.2 |
| Sex: Female, Male(Participants) | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group | Total |
|---|---|---|---|---|---|---|---|
| Female | 11 | 10 | 12 | 4 | 10 | 10 | 57 |
| Male | 15 | 16 | 14 | 22 | 16 | 14 | 97 |
| Race/Ethnicity, Customized(Participants) | AduFx Group | 2PedFx Group | PedFx Group | Adu2Fx Group | Adu1Fx Group | Control Group | Total |
|---|---|---|---|---|---|---|---|
| Asian | 1 | 3 | 2 | 2 | 1 | 0 | 9 |
| Black Or African American | 8 | 6 | 10 | 9 | 7 | 8 | 48 |
| Native Hawaiian Or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other, Not Specified | 0 | 1 | 2 | 2 | 4 | 1 | 10 |
| White | 17 | 16 | 12 | 13 | 14 | 14 | 86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from May 2017 to primary completion in Jul 2018, 13 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 39 phase 2 interventional studies under Malaria, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.